| Autor: |
McLachlan, Sue-Anne, Cameron, David, Murray, Robin, Tripathy, Debu, Bergström, Bengt |
| Předmět: |
|
| Zdroj: |
Clinical Drug Investigation; 2006, Vol. 26 Issue 1, p43, 6p |
| Abstrakt: |
The article discusses the safety of oral ibandronate in the treatment of bone metastases from breast cancer. It is reported that bone metastases cause significant morbidity, including bone pain, impaired mobility, pathological fracture and spinal cord or nerve root compression. Since breast cancer patients with bone metastases survive on average for 2.5 years, treatment strategies must be well tolerated during long-term use. The results of a trial demonstrate that once-daily oral ibandronate was well tolerated for up to 4 years. The incidence of treatment-related adverse events was low and similar in patients receiving oral ibandronate for 2 years or 4 years, with no evidence of cumulative toxicity in the group receiving it for the longer period. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
